Why the study?
Clinical use of doxorubicin is severely limited by cumulative cardiotoxicity, and no universal and highly effective protective therapy has been introduced.
Population
Rat cardiomyocytes (H9c2) and human induced-pluripotent-stem-cell-derived cardiomyocytes (hiPSC-CMs)
Comparison
Cinnamic acid derivatives against doxorubicin-induced cardiotoxicity
Design
In vitro preclinical study
Key result
Cinnamic acid derivatives protected rat and human cardiomyocytes against doxorubicin-induced cardiotoxicity by ameliorating oxidative stress, reducing caspase levels, and preventing motility inhibition.
Authors
Loading...
Does not support clinical use; leaves open further development of cinnamic acid derivatives against doxorubicin cardiotoxicity.
Cinnamic acid derivatives demonstrate multidirectional cardioprotective effects against doxorubicin-induced toxicity in vitro, suggesting potential as lead structures for novel cardioprotective therapeutics.
Koczurkiewicz et al. (2021) studied Doxorubicin-induced cardiotoxicity. Cinnamic acid (CA) derivatives vs. Doxorubicin alone / control was evaluated on Oxidative stress, viability reduction, caspase-3 and -7 levels, motility inhibition, and cytoskeleton rearrangement. Cinnamic acid derivatives protected rat and human cardiomyocytes against doxorubicin-induced cardiotoxicity by ameliorating oxidative stress, reducing caspase levels, and preventing motility inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: